SHAMROCK BIOTECH – BIOLOGICS API DIVISION
Complex Biological APIs, Drug Substances, Starting Materials & Intermediates
Shamrock Biotech, the biologicals division of Shamrock Pharma Group, is building an integrated platform for the development, manufacture and commercialization of complex biological APIs and bio-derived pharmaceutical ingredients.
The division connects diversified global sourcing of qualified biological crude and starting materials, including non-China supply lanes, with API purification, process development, analytical characterization, manufacturing at Bavla, technology transfer and global commercialization.
BIOLOGICS API DEVELOPMENT PLATFORM
Bulk, Pharmaceuticals & Chemicals Division
Qualified Biological Source → Crude / Starting Material → Purification & Process Development → Pharmaceutical-Grade API → Regulatory Support → Global Commercialization
Our strategy is built around creating traceable, diversified and commercially scalable biological supply chains, while developing manufacturing platforms across Heparin & LMWHs, Human Urinary Biologicals, Glycosaminoglycans / Heparinoids, Pulmonary Biologicals and Specialty Biological APIs.
We at SHAMROCK strongly believe if our people Organization, then R&D department are our “BRAIN”. Every year, we have more than 50 products undergoing laboratory trials from 5 gms to 100 gms and kilo-scale from 1 kg to 5 kgs. Thus several products are available with us in laboratory scale process to be taken up for Pilot or Commercial Production.
With the single minded aim of innovation, our technical and developmental team in the R&D Laboratory specialize in development of new processes, designing to ensure non-infringement of patents by applying alternate synthetic process and innovating current processes for adding value to the products and decreasing the production costs. The objective is “total satisfaction of our Customers whether it is gram, kilogram or multi-ton quantity”.
Key Platforms
Heparin & LMWHs | Human Urinary-Derived Biologicals | GAG / Heparinoids | Pulmonary & Lung-Derived Biologicals | Specialty Biological APIs | Veterinary Biologicals
Selected API Portfolio
Heparin Sodium | Enoxaparin Sodium | Dalteparin Sodium | Nadroparin Calcium | Bemiparin Sodium | Heparin Calcium | hCG | hMG / Menotropins | Ulinastatin | Urokinase | Sulodexide | Dermatan Sulfate | Aprotinin | Defibrotide | Poractant Alfa | Pulmonary Surfactants
Our Strength
Diversified Global Sourcing | Non-China Supply Development | Biological Traceability | API Manufacturing | Process Development | Technology Transfer | Regulatory Support | Global Market Access
Positioning Line
From biological source crude to pharmaceutical-grade API and global market access. We procure high quality Crude and raw materials for Latin America – LATAM, U.S.A and Europe with ZERO Dependency on China for our biologic crude supply.
Critical Care
Specialty Injectable & Biological FDFs for Hospital, ICU & Emergency Medicine
Shamrock Pharma Group’s Critical Care Division brings together specialty injectables, biological FDFs and high-value hospital products within an integrated development, manufacturing and commercialization platform.
The division connects qualified and diversified global sourcing, including non-China biological starting materials, with API development and manufacturing, specialized FDF CMO production, technology transfer, dossier ownership, regulatory registration and global market access.
Integrated Critical Care Platform
Qualified Crude & Starting Materials → API Development & Manufacturing → Specialty Injectable / Biological FDF → CMO/CDMO → Dossier & Registration → Global Commercialization
Our strategy is built around creating scalable manufacturing platforms rather than individual molecules, combining Unimark Remedies LTD, Bavla – R&D Centre; Biologics API capabilities, qualified FDF CMO partners and buyer-backed regulatory and market-development pathways to build a resilient and commercially viable critical-care portfolio.
